Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 2/2016

01-02-2016 | Original Article – Clinical Oncology

Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins

Authors: Tanja Ignatov, Holm Eggemann, Elke Burger, Serban Dan Costa, Atanas Ignatov

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2016

Login to get access

Abstract

Background

The survival effect of adjuvant radiotherapy (RT) for vulvar cancer has been poorly investigated.

Patients and methods

We performed a multicentre retrospective register study of 257 patients with primary squamous vulvar cancer. The survival effect of adjuvant RT was investigated in two groups of patients, dependent on surgical margins. The outcome measure was overall survival. All statistical tests were two-sided.

Results

Of the 257 patients investigated, 192 had negative resection margins, while positive and/or close surgical margins were observed in 65 cases. Margin status was associated with unfavourable overall survival. The five-year overall survival was 66.1 and 49.2 % in patients with negative and positive/close resection margins, respectively. Adjuvant RT directed to the vulva was associated with improved survival in patients with positive/close resection margins but not in patients with negative surgical margins. The 5-year overall survival of patients with positive/close surgical margins without RT was 29 %, whereas with RT it increased to 67.6 %. Notably, patients with positive/close surgical margins who received RT of the vulva had a 5-year survival rate similar to the patients with negative margins (67.6 %). Multivariate analysis adjusted for age, stage of disease, tumour grade and lymph node metastases showed that adjuvant RT significantly reduced the mortality risk in patients with positive/close resection margins (HR 0.36, CI 0.14–0.94, p = 0.038). In the group of patients with negative resection margins, the involvement of lymph nodes was the strongest unfavourable prognostic factor.

Conclusions

Adjuvant RT should be used for patients with positive/close surgical margins to improve their outcome.
Literature
go back to reference Busch M, Wagener B, Schaffer M, Duhmke E (2000) Long-term impact of postoperative radiotherapy in carcinoma of the vulva FIGO I/II. Int J Radiat Oncol Biol Phys 48:213–218PubMedCrossRef Busch M, Wagener B, Schaffer M, Duhmke E (2000) Long-term impact of postoperative radiotherapy in carcinoma of the vulva FIGO I/II. Int J Radiat Oncol Biol Phys 48:213–218PubMedCrossRef
go back to reference Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, Osann K, Cheung MK, Berman ML, Disaia PJ (2007) Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 104:636–641PubMedCrossRef Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, Osann K, Cheung MK, Berman ML, Disaia PJ (2007) Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 104:636–641PubMedCrossRef
go back to reference de Hullu JA, van der Zee AG (2006) Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 60:38–58PubMedCrossRef de Hullu JA, van der Zee AG (2006) Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 60:38–58PubMedCrossRef
go back to reference Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A (2015) Moderate HER2 expression as prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22:725–733PubMedCrossRef Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A (2015) Moderate HER2 expression as prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22:725–733PubMedCrossRef
go back to reference Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW (1997) Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys 38:381–389PubMedCrossRef Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW (1997) Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys 38:381–389PubMedCrossRef
go back to reference Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR (2006) Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 60:227–241PubMedCrossRef Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR (2006) Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 60:227–241PubMedCrossRef
go back to reference Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS (1990) Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 38:309–314PubMedCrossRef Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS (1990) Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 38:309–314PubMedCrossRef
go back to reference Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A (2015) Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. Breast Cancer Res Treat 151:357–364PubMedCrossRef Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A (2015) Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. Breast Cancer Res Treat 151:357–364PubMedCrossRef
go back to reference Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA (2006) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018–1022PubMedCrossRef Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA (2006) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018–1022PubMedCrossRef
go back to reference Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L (2015) Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 107:dju426PubMedPubMedCentralCrossRef Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L (2015) Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 107:dju426PubMedPubMedCentralCrossRef
go back to reference Pao WM, Perez CA, Kuske RR, Sommers GM, Camel HM, Galakatos AE (1988) Radiation therapy and conservation surgery for primary and recurrent carcinoma of the vulva: report of 40 patients and a review of the literature. Int J Radiat Oncol Biol Phys 14:1123–1132PubMedCrossRef Pao WM, Perez CA, Kuske RR, Sommers GM, Camel HM, Galakatos AE (1988) Radiation therapy and conservation surgery for primary and recurrent carcinoma of the vulva: report of 40 patients and a review of the literature. Int J Radiat Oncol Biol Phys 14:1123–1132PubMedCrossRef
go back to reference Perez CA, Grigsby PW, Chao C, Galakatos A, Garipagaoglu M, Mutch D, Lockett MA (1998) Irradiation in carcinoma of the vulva: factors affecting outcome. Int J Radiat Oncol Biol Phys 42:335–344PubMedCrossRef Perez CA, Grigsby PW, Chao C, Galakatos A, Garipagaoglu M, Mutch D, Lockett MA (1998) Irradiation in carcinoma of the vulva: factors affecting outcome. Int J Radiat Oncol Biol Phys 42:335–344PubMedCrossRef
go back to reference Piura B, Masotina A, Murdoch J, Lopes A, Morgan P, Monaghan J (1993) Recurrent squamous cell carcinoma of the vulva: a study of 73 cases. Gynecol Oncol 48:189–195PubMedCrossRef Piura B, Masotina A, Murdoch J, Lopes A, Morgan P, Monaghan J (1993) Recurrent squamous cell carcinoma of the vulva: a study of 73 cases. Gynecol Oncol 48:189–195PubMedCrossRef
go back to reference Rouzier R, Haddad B, Plantier F, Dubois P, Pelisse M, Paniel BJ (2002) Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 100:1159–1167PubMedCrossRef Rouzier R, Haddad B, Plantier F, Dubois P, Pelisse M, Paniel BJ (2002) Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 100:1159–1167PubMedCrossRef
go back to reference Rouzier R, Haddad B, Atallah D, Dubois P, Paniel BJ (2005) Surgery for vulvar cancer. Clin Obstet Gynecol 48:869–878PubMedCrossRef Rouzier R, Haddad B, Atallah D, Dubois P, Paniel BJ (2005) Surgery for vulvar cancer. Clin Obstet Gynecol 48:869–878PubMedCrossRef
go back to reference Viswanathan AN, Pinto AP, Schultz D, Berkowitz R, Crum CP (2013) Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol 130:545–549PubMedCrossRef Viswanathan AN, Pinto AP, Schultz D, Berkowitz R, Crum CP (2013) Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol 130:545–549PubMedCrossRef
go back to reference von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457CrossRef von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457CrossRef
go back to reference Woelber L, Choschzick M, Eulenburg C, Hager M, Jaenicke F, Gieseking F, Kock L, Ihnen M, Petersen C, Schwarz J, Mahner S (2011) Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva. Ann Surg Oncol 18:3811–3818PubMedCrossRef Woelber L, Choschzick M, Eulenburg C, Hager M, Jaenicke F, Gieseking F, Kock L, Ihnen M, Petersen C, Schwarz J, Mahner S (2011) Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva. Ann Surg Oncol 18:3811–3818PubMedCrossRef
go back to reference Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jaenicke F, Mahner S (2013) Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol 5:183–192PubMedPubMedCentralCrossRef Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jaenicke F, Mahner S (2013) Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol 5:183–192PubMedPubMedCentralCrossRef
Metadata
Title
Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins
Authors
Tanja Ignatov
Holm Eggemann
Elke Burger
Serban Dan Costa
Atanas Ignatov
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 2/2016
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-2060-9

Other articles of this Issue 2/2016

Journal of Cancer Research and Clinical Oncology 2/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.